Introduction {#Sec1}
============

The incidence of oral cavity/pharynx and larynx cancer in Europe was estimated to 100,000 and 40,000, respectively, in 2012 \[[@CR1]\]. In Norway, 800 patients were diagnosed with head and neck cancer (HNC) in 2014, representing 2.5% of the total incidence of malignant disease \[[@CR2]\].

Management of HNC is multi-disciplinary; surgery, radiotherapy (RT) with or without concomitant chemotherapy. High dose RT (prescribing doses typically of 70 Gy) is necessary to achieve cure, but may result in side effects. The employment of three-dimensional conformal radiotherapy (3D CRT) and intensity-modulated radiotherapy (IMRT) have permitted treatment largely conforming to the disease extensions for the individual patient \[[@CR3]--[@CR6]\]. However, each year, 30--50% of patients with locally advanced HNC, experience loco-regional relapse \[[@CR7]\]. Loco-regional recurrence is still one of the major causes of failure in HNC after radical treatment \[[@CR7]\]. Therefore, it is important to evaluate the patterns of loco-regional recurrences in patients treated with 3D CRT and IMRT. Specifically, it is relevant to learn more about the cause of relapse, the dose delivered to the tissue in question and the proximity of the tumor recurrence to the original target structures. To address this issue, we have analyzed recurrence patterns in patients with recurrent HNC previously treated with 3D CRT and IMRT at our institution. A detailed mapping of the primary treatment, the patient dose distributions and subsequent recurrence patterns are provided.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

We retrospectively reviewed the medical records of 112 patients with primary squamous cell carcinoma in the head and neck reirradiated between January 2007-December 2013. To be included in the current study the following criteria had to be fulfilled: i) re-irradiation for first relapse in the head and neck region, ii) radiotherapy for both primary and recurrent disease at Oslo University Hospital, iii) Computed Tomography (CT), and/or Positron Emission Tomography (PET)/magnetic resonance images (MRI) taken prior to RT, iv) available RT dose plans for the primary and recurrent disease which were technically possible to co-register, v) completed their planned curative primary radiation treatment.

Of the 112 patients, 26 patients fulfilled the inclusion criteria. The general characteristics of the patients and tumor site are detailed in Table [1](#Tab1){ref-type="table"}. The patterns of recurrence were analyzed separately in 2 groups of patients based on the primary treatment they received; patients treated with primary RT (*n* = 10) and postoperative RT (*n* = 16). The time difference between primary RT and reirradiation varied between 4 and 63 months (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). At the time of recurrence, 16 of 26 patients had their gross tumor removed before reirradiation. In these patients, the gross tumor was delineated on the relapse RT CT images based on the diagnostic CT examination taken prior to relapse surgery.Table 1Patients characteristicsNumber of patientsTotal26Median age65.5(42--86)Sex Male20 Female6Postoperative radiotherapy16Primary radiotherapy10Chemotherapy Yes2 No24Tumor site Oral cavity13 Parotid gland2 Epipharynx4 (Case No. 2, 22 and 24) Larynx4 Tonsilla2 Nasal cavity1Radiotherapy technique IMRT12 3D conformal14 Table 2Primary treatment history -- Patients treated with primary RTCase nrRadiotherapy regimenRadiotherapy techniqueTreatment yearTime difference between first RT and recurrence RT (In months)TNMFraction D × No of fractions +/− concomitant boost (CB) or hyperfractionated RT (HF)/Total DoseIMRT = I and Conformal = C12 Gy × 23 + CB 2 Gy × 12/70 GyI200919T4N1M02HF 1.5 Gy × 20 + 1.5 Gy × 20/60 GyC200914T4N2bM032 Gy × 23 + CB 2 Gy × 12/70 GyI200919T2N2bM042 Gy × 23 + CB 2 Gy × 12/70 GyC200841T4N2aM051.5 × 15 + 1.75 × 4 + 1.5 × 20/59.5 GyI20105T4N0M162 Gy × 23 + CB 2 Gy × 12/70 GyC200963T2N0M072 Gy × 23 + CB 2 Gy × 12/70 GyC200822T3N0M082 Gy × 23 + CB 2 Gy × 11/68 GyI201010T4aNxM092 Gy × 23 + CB 2 Gy × 12/70 GyI200918T2N0M0102 Gy × 23 + CB 2 Gy × 12/70 GyI200910T3N2bM0 Table 3Primary treatment history -- Patients treated with postoperative RTCase nrRadiotherapy regimenRadiotherapy techniqueTreatment yearTime difference between first RT and recurrence RT (In months)TNMFraction D × No of fractions +/− concomitant boost (CB) or hyperfractionated RT (HF)/Total DoseIMRT = I and Conformal = C112 Gy × 23 + CB 2 Gy × 2/50 GyC201033T1N0M0122 Gy × 23 + CB 2 Gy × 12/60 GyC200743T4N0M0132 Gy × 25/50 GyC20116T1N0M0142 Gy × 23 + CB 2 Gy × 10/66 GyI201135T2N0M0152 Gy × 35/70 GyC201010T1N0M0162 Gy × 23 + 2 Gy × 7 + 2 Gy × 3/66 GyI20124T2N2bM0172 Gy × 23 + 2 Gy × 7/60 GyI20116T2N2bM0182 Gy × 23 + 2 Gy × 7/60 GyC201014T1N2bM0192 Gy × 23 + CB 2 Gy × 7/60 GyC200910T1N0M0202 Gy × 23 + 2 Gy × 2/50 GyC20126T1N0M0212 Gy × 23 + 2 Gy × 7/60 GyC20107T2N1M0222 Gy × 33/66 GyI200935T4N0M0232 Gy × 23 + 2 Gy × 2/50 GyI20139T2N0M0242 Gy × 23 + 2 Gy × 2/50 GyI200659T3N2M0252 Gy × 23 + 2 Gy × 7/60 GyC20107T2N2bM0262 Gy × 23 + 2 Gy × 2/50 GyC20105T2N0M0

Only 2 of the 26 patients received concomitant chemotherapy (Table [1](#Tab1){ref-type="table"}). For the primary treatment, 12 of 26 patients received IMRT while 14 patients were treated with 3D CRT for their HNC disease as reported in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.

Tumor delineation {#Sec4}
-----------------

Tumor volumes were defined by an experienced radiation oncologist on simulation CT images acquired in conjunction with primary and recurrent RT, registered in some cases with MRI and/or Fluorodeoxyglucose (18 F-FDG) PET images. The gross tumor volume (GTV; GTVp for primary GTV and GTVr for recurrence GTV) was defined as the visible tumor based on all available diagnostic imaging as well as clinical examination. The high risk and standard risk areas with 10 mm margin to GTV was included in the clinical target volume (CTV, CTVp and CTVr). CTV also included non-dissected lymph nodes. The planning target volume (PTV, PTVp and PTVr) was constructed by expanding the corresponding CTV by 3 mm \[[@CR8], [@CR9]\].

Image registration and overlap definition {#Sec5}
-----------------------------------------

Relapse localization on CT images was further investigated by using the software module Oncentra Masterplan (version 4.3). The recurrence treatment planning CT for each included patient was exported to the respective primary dose plan-CT series. The exported recurrence dose plan CT was further rigidly registered with the primary dose plan-CT for each patient using available image registration tools. To achieve an optimal image registration, the information such as skull base, frontal bone and other bony structures were used. After CT image registration, the GTVr from the recurrence dose plan-CT was copied and pasted into the primary dose plan CT dataset. The HNC oncologist (JFE) also approved the quality of image registration for each included patient (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Fusion display of primary (gray) and recurrence (pink) CT images

To assess overlaps, the GTVr overlapping with the GTVp in each primary CT slice was identified and delineated as illustrated in Fig. [2](#Fig2){ref-type="fig"}. For cases with relapses located fully or partly in the elective nodes, no overlap volume was assessed. Then the dose of both the primary RT plan and of the reirradiation plan in the overlap area was calculated.Fig. 2Definition of overlap volume

To explain the cause of relapse, it was assessed whether the relapse occurred in the regional lymph nodes or not. The localization of the regional lymph node relapse was assessed by our oncologist.

The epicenter in GTVr and GTVp were defined, the dose and distance between the 2 epicenters were calculated. Epicenter was estimated from the center of mass. A mean epicenter distance value was calculated in cases with more than one GTVr.

The recurrence volumes were considered as in-field, marginal and out-of-field, if the dose in the epicenter of the recurrence volume was located in high, low or very low dose areas, respectively. Cases with their relapse located in 2 regional lymph nodes with different location, were labelled with 2 relapse site definitions but one mean epicenter dose.

Statistics {#Sec6}
----------

To assess the dose differences when employing IMRT or 3D CRT, a two-tailed independent *T*-test was employed. A *p* value \< 0.05 was considered as statistically significant.

Ethics {#Sec7}
------

All necessary approvals were obtained before the study was conducted. Written informed consent was obtained from all patients in accordance with the procedures of the Data Protection Office of whom also approved this study.

Results {#Sec8}
=======

The range of the total prescribed RT dose for primary HNC treatment was 50--70 Gy, as shown in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. In total 13 (50%) of the failures occurred within 1 year after primary treatment, 6 (23%) within 2 years and 7 (27%) within 3 to 5 years. In patients treated with postoperative RT compared to those treated with primary RT, the fraction of the recurrences occurring within 1 year was approximately 3 times higher. The fraction of patients with relapse within 2 years was 4 times higher in the patient group treated with primary RT compared to postoperative RT patient group. The fraction of patients with relapse within 3--5 years after primary treatment was identical in both patient groups.

The population-averaged median dose to the recurrence volume for 26 patients receiving either IMRT or 3D CRT was 65.3, and 45.1 Gy, respectively (Data not shown). No statistically significant dose differences were observed between the employed RT techniques.

Recurrence occurred in the regional lymph nodes in 4 out of 10 patients treated with primary RT compared to 11 out of 16 patients treated with postoperative RT as shown in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}.Table 4Site of relapse for patients with primary RTCase No.Site of relapseLocation of relapse in lymph node (yes = y or No = N)Total relapse dose (Gy) as a result of first RT1Partly inside the primary tumor volumeN71.02Outside the primary tumor volume and elective lymph node volumeY27.03Partly inside the primary tumor volumeY67.04Partly inside the primary tumor volume and elective lymph node volumeY67.05Partly inside the primary tumor volumeN43.06Fully inside the primary tumor volumeN69.07Partly inside the elective lymph node volumeY50.08Fully inside the primary tumor volumeN68.09Partly inside the elective lymph node volume and touches the primary tumor volumeN64.010Partly inside the primary tumor volume and elective lymph node volumeN70.0 Table 5Site of relapse for patients treated with postoperative RTCase No.Site of relapseLocation of relapse in lymph node (yes = y or No = N or partly = P)Total relapse dose (Gy) as a result of first RT11Relapse in a lymph node partly inside the elective lymph node volume and the other lymph node outside the elective lymph node volume and the primary tumor volumeY44.0 and 45.012Partly inside the primary tumor volumeN52.013Fully outside the primary tumor volume and elective lymph node volumeY15.014Partly inside the elective lymph node volumeY20.015Fully inside the primary tumor volumeN66.016Partly inside the elective lymph node volume and primary tumor volumeN60.017Relapse in one lymph node volume partly inside the elective lymph node volume and another lymph node fully inside the elective lymph node volumeY9.0 And 47.018Fully inside the elective lymph node volumeY59.019Partly inside the elective lymph node volumeY60.020Fully inside the elective lymph node volumeY38.021Fully inside the elective lymph node volumeY45.022Partly inside the primary tumor volumeN66.023Outside the elective lymph node volume and primary tumor volumeY2.024Partly inside the primary tumor volumeN50.025Outside the elective lymph node volume and primary tumor volumeY9.026Fully inside the elective lymph node volume and also touches the primary tumor volumeY41.0

Total relapse dose in patients who received primary RT varied from 27 to 71 Gy and in the patients treated with postoperative RT from 2 to 66 Gy (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). The dose in epicenters and distance between epicenters in GTVr and GTVp are shown in the Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}.

There were 1 and 3 out-of-field recurrences in patients treated with primary RT and postoperative RT, respectively. One of 10 patients treated with primary RT and 2 of 16 patients treated with postoperative RT had marginal relapses (Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). Eight and 11 in-field recurrences were identified in patients treated with primary RT and postoperative RT, respectively (Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). The GTVr and GTVp epicenter distance in patients treated with primary RT and postoperative RT was 0.4--6.1 and 1.2--13.7 cm, respectively. The average epicenter distance for in-field, marginal and out-of-field recurrences were 3.8, 6.3 and 9.4 cm.Table 6Patient treated with primary RT; recurrence volume size, recurrence site, overlap volume size, epicenter dose and distance between epicenter in GTVr and GTVpCase No.Recurrence volume (ccm)In-fieldMarginalOut-of- fieldOverlap size (ccm)Epicenter dose (Gy) in GTVr/GTVp and distance (cm)16.5X4.071.4/70.2, 0.9217.4X0.034.4/60.0, 5.2373.7X17.169.2/71.2, 3.7444.3X23.872.8/71.6, 1.7576.0X18.356.2/61.5, 1.8674.7X15.871.5/71.6, 0.4741.1X0.054.7/72.4, 4.5815.6X15.067.8/66.7, 3.0946.4X7.370.5/71.2, 4.21014.2X7.370.2/68.8, 2.8 Table 7Patient treated with postoperative RT; recurrence volume size, recurrence site and overlap volume size, epicenter dose and distance between epicenter in GTVr and GTVpCase No.Recurrence volume (ccm)In-fieldMarginalOut-of- fieldOverlap size (ccm)Epicenter dose (Gy) and distance (cm)1188.9X0.0/0.044/49.2, 6.61224.2X1.548.8/61.5, 5.51376.6X0.00.7/50.8, 12.01418.0X0.066.4/65.2, 2.8155.8X2.665.5/69.0, 2.91686.6X37.764.3/61.7, 4.91720.1X0.0/0.044.0/59.9, 8.8185.2X0.063.0/58.6, 4.9192.1X0.062.9/62.7, 5.22018.2X0.045.3/50.4, 9.22159.5X32.645.8/57.8, 9.32213.5X9.565.2/69.7, 1.223119.3X0.01.6/49.8, 13.72427.2X4.352.7/52.7, 2.82559.0X0.06.9/59.6, 6.72627.1X1.346.4/49.7, 4.1 Fig. 3Schematic representation of 26 recurrences included in this study. Patients treated with primary RT and postoperative RT are shown with case number in black and red, respectively

The size of recurrence volume varied between 6.5 to 76 ccm and 2.1 to 119.3 ccm in patients treated with primary RT and postoperative RT, respectively (Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}).

The mean overlap size for primary RT was 10.4 ccm (SD ± 8.6) compared to patient group receiving postoperative RT of 5.6 ccm (SD ± 11,8) (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}) (*p* = 0.23).

Discussion {#Sec9}
==========

This study analyzed the failure patterns of 26 HNC patients treated with RT for their relapse disease. Our analyses show that the majority of the failures occurred within 1 year after completed primary treatment. There was no statistical difference in the doses to the recurrence volume in patients treated with IMRT or 3D CRT technique. The majority of the recurrence in the patients treated with postoperative RT occurred in the regional lymph nodes. The recurrent lymph nodes were located fully or partly inside the elective lymph node region in the majority of these patients. The majority of recurrences were recognized as in-field, independent of the primary treatment.

Due et al. \[[@CR10]\] have analyzed the recurrence pattern in 39 HN squamous cell carcinoma patients with loco-regional failure treated with chemoradiation. Due and colleagues \[[@CR10]\] reported that 96% of recurrences were located in the high dose region. Another study carried out by Soto et al. \[[@CR11]\] showed that 100% (9/9) of the included HNC patients with loco-regional failure were located inside the primary GTV. The shorter average epicenter distance of 3.8 cm between GTVr and GTVp, the high epicenter dose in GTVr and the reported site of recurrences in this study show that the majority of recurrences (73%) are also located in high dose area in accordance with the studies of Due et al. and Sot et al. \[[@CR10], [@CR11]\].

In the study of Due et al. \[[@CR10]\] all the included patients were treated with primary RT, while in the current study only 10 of the included patients received primary RT and 16 patients were treated with postoperative RT. Our results showed no correlation between the recurrence patterns and the kind of primary treatment the patients had received. The cause of relapse in the study of Due et al. \[[@CR10]\] seems to be insufficient total dose to the primary GTV. However, in the present study the relapse could be due to: i) inadequate total dose to the primary target volume and/or ii) imprecise diagnostic imaging of the primary tumor volume leading to inadequate primary target delineation. In the majority of the cases (15/26) in our study, regional recurrences occurred in lymph nodes partly or fully located in the area of the primary GTV or elective lymph nodes. Therefore, it may be questioned whether the total dose in this area was adequate or not. In the marginal and out-of-field recurrences the cause of relapse seems to be due to the insufficient primary target delineation. Increased use of FDG-PET in defining the GTV as discussed in the study of Soto et al. \[[@CR11]\] could probably improve the accuracy of the tumor definition.

IMRT and 3D CRT techniques are usually employed in the standard management of HNC patients. In only one of the marginal recurrences in this study IMRT technique was used in the delivery of their primary RT. Increased risk of marginal misses is often mentioned as one of the disadvantages associated with IMRT \[[@CR12]\]. Precise target definition is therefore crucial to avoid marginal miss.

One limitation of the current study is the heterogeneity of the patient cohort and their stage of disease. However, it is important to stress that the goal of this study was to assess the relapse localization and the cause of it. Another limitation is that the CT slice thickness in primary and recurrence CT scans were not always identical. This may have resulted in less precise fusion of the primary and relapse CT scans. In general, some uncertainty can be associated with the rigid registration process because of anatomical changes between the primary and recurrence RT. However, our experienced oncologist has studied the detailed disease information in each medical record and diagnostic CT images and compared them with the recurrence localization assessed after registration. Another limitation when using rigid registration is inaccurate estimate of the dose distribution in the CT series of the recurrence volume.

Conclusion {#Sec10}
==========

The cause of recurrence in the majority of the patients seems to be inadequate dose to the primary treatment volume and in some few cases due to imprecise primary diagnostic imaging leading to inadequate primary target delineation. The majority of recurrences were recognized as in-field, independent of the primary treatment. Further investigation is necessary to evaluate the total RT dose needed to treat the primary HNC. Optimal diagnostic methods should be employed to avoid poor primary target delineation.
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